Effects Of Cocaine In Rats Research Articles

Lesions of the dorsomedial frontal cortex block sensitization to the positive-reinforcing effects of cocaine

Previous studies have reported that rats exposed to a binge-abstinence history of cocaine self-administration exhibit sensitization to the positive-reinforcing effects of cocaine on a progressive ratio (PR) schedule of reinforcement. The purpose of the present study was to determine whether lesions of the dorsomedial frontal cortex block sensitization to the reinforcing effects of cocaine in rats with a history of binge-abstinence self-administration. Separate groups of male rats received bilateral infusions of either ibotenic acid (lesion) or sterile saline (sham) into the dorsomedial frontal cortex, or were left undisturbed (intact). All rats were then implanted with jugular catheters and trained to self-administer cocaine. Following acquisition, cocaine was made available on a PR schedule of reinforcement and breakpoints were determined in each group. Rats were then exposed to a discrete-trials (DT) procedure in which cocaine was made available during 10-min discrete-trials that occurred every 15 min (i.e., 4 times per hr) during daily, 24-hr sessions. This procedure elicited a “binge” in all groups, during which high rates of responding were maintained over a period of 1–2 days. After 10 days, the DT procedure was terminated, and no cocaine was available for the next 7 days. Following 7 days of forced “abstinence”, cocaine-reinforced breakpoints were redetermined on the PR schedule. Prior to the DT procedure, no differences were observed in breakpoints across the three groups. Following the 7-day abstinence period, breakpoints on the PR schedule increased significantly in intact and sham rats, indicating an increase in the reinforcing efficacy of cocaine. In contrast, breakpoints did not increase in lesion rats, and were similar to those obtained prior to the binge-abstinence history. These data suggest that lesions of the dorsomedial frontal cortex block sensitization to the positive-reinforcing effects of cocaine in rats with a history of binge-abstinence self-administration.

Muscarinic preferential M 1 receptor antagonists enhance the discriminative-stimulus effects of cocaine in rats

Previous studies of benztropine analogues have found them to inhibit dopamine uptake like cocaine, but with less effectiveness than cocaine in producing behavioral effects related to drug abuse. Studies have assessed whether nonselective muscarinic antagonists decrease the effects of cocaine because many of the benztropine analogues are also muscarinic antagonists. As previous studies were conducted with nonselective muscarinic antagonists and the benztropine analogues show preferential affinity for the M 1 muscarinic receptor subtype, the present study examined interactions of cocaine and the preferential M 1 antagonists, telenzepine (TZP) and trihexyphenidyl (TXP) on subjective effects in rats trained to discriminate cocaine (10 mg/kg, i.p.) from saline injections. Cocaine dose-dependently increased the percentage of responses on the cocaine-appropriate lever, with full substitution at the training dose. In contrast neither TZP nor TXP produced more than 25% cocaine-appropriate responding at any dose. Both M 1 antagonists produced significant leftward shifts in the cocaine dose–effect curve, TZP at 3.0 and TXP at 0.3 and 1.0 mg/kg. The present results indicate that preferential antagonist actions at muscarinic M 1 receptors enhance rather than attenuate the discriminative-stimulus effects of cocaine, and thus those actions unlikely contribute to the reduced cocaine-like effects of BZT analogues.

Effects of group I metabotropic glutamate receptor antagonists on the behavioral sensitization to motor effects of cocaine in rats

Metabotropic glutamate receptors (mGluRs) were reported to regulate various behavioral effects of addictive drugs. The present study evaluated the role of group I mGluRs in the progressive augmentation ("sensitization") of the behavioral effects observed after repeated, intermittent cocaine exposure. After habituation to handling and baseline activity measurement (days 1-2), rats received eight injections of cocaine (10 mg/kg) or saline on days 3-6, 8-11, and then, were tested twice with acute saline and cocaine given in a counterbalanced manner on days 13 and 15. Before the test sessions, subjects were pretreated with mGluR1 antagonist EMQMCM (JNJ16567083, (3-ethyl-2-methyl-quinolin-6-yl)-(4-methoxy-cyclohexyl)-methanone methanesulfonate) and mGluR5 antagonist MTEP ([(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine). Pretreatment with EMQMCM (2.5-10 mg/kg) but not MTEP (2.5-10 mg/kg) significantly reduced expression of the sensitized ambulatory motor activity of the cocaine-experienced animals acutely challenged with cocaine. Both EMQMCM and MTEP significantly reduced vertical motor activity across all cocaine/saline treatment conditions. These findings indicate that the expression of behavioral sensitization to cocaine-induced stimulation of locomotor activity may be modulated by group I mGluR antagonists (mGluR1 rather than mGluR5), but these effects occur at the dose levels that attenuate vertical activity.

Previous Exposure to THC Alters the Reinforcing Efficacy and Anxiety-Related Effects of Cocaine in Rats

The hypothesis that prior cannabis exposure increases the likelihood of becoming addicted to other drugs can be evaluated by giving rats a history of tetrahydrocannabinol (THC) exposure, then allowing them to self-administer other drugs. In Experiment 1, THC pre-exposure did not alter the acquisition of cocaine self-administration or the amount of cocaine taken under a fixed-ratio 1 (FR1) schedule, with one response required for each injection. Under a progressive-ratio schedule, with the response requirement increasing exponentially with each injection, cocaine-seeking was significantly reduced in THC-exposed rats, suggesting that the regimen of THC exposure used in the present study caused cocaine to be devalued as a reinforcer. In contrast, in an earlier study that used the same regimen, a history of THC exposure did not alter the value of heroin as a reinforcer under the progressive-ratio schedule, but it increased heroin self-administration under the FR1 schedule. Experiment 2 examined how this regimen of THC pre-exposure alters the locomotor effects of cocaine and heroin. THC pre-exposure produced cross-tolerance to the motor-depressant effects of heroin; this may explain the shortened post-injection pauses exhibited by THC-exposed rats under FR1 heroin self-administration. When given cocaine, THC-exposed rats exhibited normal increases in locomotion, but they avoided the center of the open field, suggesting that this THC pre-exposure regimen enhances the anxiogenic effects of cocaine. This enhanced anxiogenic effect-which was verified in Experiment 3 using another model of anxiety, the light-dark test-may explain the reduced reinforcing value of cocaine observed in THC-exposed rats in Experiment 1.

Interaction of the tachykinin NK 3 receptor agonist senktide with behavioral effects of cocaine in marmosets ( Callithrix penicillata)

Brain neuropeptide transmitters of the tachykinin family are involved in the organization of many behaviors. However, little is known about their contribution to the behavioral effects of drugs of abuse. Recently, antagonism of the tachykinin NK 3-receptor (NK 3-R), one of the three tachykinin receptors in the brain, was shown to attenuate the acute and chronic behavioral effects of cocaine in rats and the acute effects in non-human primates. In order to expand these findings we investigated the effects of the NK 3-R agonist, succinyl-[Asp 6, Me-Phe 8]SP 6-11 (senktide), on the acute behavioral effects of cocaine in marmoset monkeys ( Callithrix penicillata) using a figure-eight maze procedure. Animals were pretreated with senktide (0, 0.1, 0.2, 0.4 mg/kg, s.c.), and received either a treatment with cocaine (10 mg/kg) or saline (i.p.). Cocaine increased locomotor activity and the duration of aerial scanning behavior, but reduced exploratory activity, bodycare activity, the frequency of aerial scanning, and terrestrial glance behavior. Senktide blocked the effects of cocaine on locomotor activity, but enhanced the cocaine effects on exploratory activity, aerial scanning frequency, and terrestrial glance behavior. Senktide alone did not significantly influence monkey behavior in this study. These data expand previous findings suggesting a complex role of the NK 3-R in the acute behavioral effects of cocaine in non-human primates.

The tachykinin NK 3 receptor antagonist SR142801 blocks the behavioral effects of cocaine in marmoset monkeys

Brain neuropeptide transmitters of the tachykinin family are involved in the organization of many behaviors. However, little is known about their contribution to the behavioral effects of drugs of abuse. Recently, the tachykinin NK 3 receptor, one of the three tachykinin receptors in the brain, was shown to attenuate the acute and chronic behavioral effects of cocaine in rats. In order to test if these findings can be generalized to primates we investigated the role of the tachykinin NK 3 receptor in the acute behavioral effects of cocaine in marmoset monkeys ( Callithrix penicillata) using a figure-eight maze procedure. Animals were pretreated with the tachykinin NK 3 receptor antagonist, ( R)-( N)-[1-[3-[1-benzoyl-3-(3,4-dichlorophenyl)piperidin-3-yl]propyl]-4-phenylpiperidin-4-yl]- N-methylacetamide (SR142801; 0, 0.02, 0.2, 2.0 mg/kg, i.p.), and received either a treatment with cocaine (10 mg/kg, i.p) or saline (i.p.). Cocaine increased locomotor activity and aerial glance behavior, but reduced exploratory and bodycare activities, scent marking and terrestrial scanning behavior. A sensitivity analysis revealed that two responder types can be differentiated in relation to the occurrence of a hyperlocomotor response to cocaine. SR142801 blocked the actions of cocaine on several behaviors dose-dependently for each responder type, respectively. There was no effect of SR142801 alone on any behavior measured. These data suggest that the tachykinin NK 3 receptor contributes to the individual behavioral response to cocaine in marmoset monkeys. Having no behavioral effects on its own, but blocking the cocaine effects, might suggest the tachykinin NK 3 receptor antagonist, SR142801, as a potential treatment of cocaine addiction in humans.

Discrete-trials heroin self-administration produces sensitization to the reinforcing effects of cocaine in rats

The prevalence of cocaine use in opioid-dependent individuals is reportedly high, and the associated negative health and social consequences are severe and well documented. Sensitization of the reinforcing effects of cocaine has been demonstrated following noncontingent opioid exposure in animals; however, no preclinical studies have investigated the impact of opioid self-administration on cocaine's reinforcing effects. Experiments were designed to investigate whether access to heroin self-administration altered the subsequent reinforcing effects of cocaine. Baseline responding for cocaine under a progressive ratio schedule was first established. Heroin was then self-administered under a 24-h discrete-trials procedure (DT5; access to heroin five times per hour). Subsequently, cocaine-maintained responding was reassessed. Here we demonstrate that 10 days of DT5 heroin self-administration (50 microg/kg per infusion) resulted in an increase in cocaine's reinforcing effects at several doses across the cocaine dose-effect curve (0.38-3.0 mg/kg per infusion). These increases were relatively long lasting, exceeding the time course of a mild withdrawal syndrome. The DT5x10-day history of heroin self-administration resulted in an upward shift in the cocaine dose-effect curve, suggesting that DT5 heroin self-administration produced an increase in potency and sensitization of the maximal effectiveness with which cocaine functions as a reinforcer. The present experiments contribute to a growing amount of preclinical evidence suggesting an impact of opioid exposure on the reinforcing effects of cocaine, which may partially explain the high incidence of cocaine use in opioid-dependent individuals.

Time of day alters long-term sensitization to cocaine in rats

To test the hypothesis that time of day influences the locomotor effects of cocaine in rats, we measured short- and long-term sensitization to cocaine at five different Zeitgeber times (ZT). Short-term sensitization was expressed equally at all ZTs tested. Long-term sensitization was expressed only at dark onset, suggesting a possible influence of melatonin. Exogenous melatonin given immediately before cocaine challenge slightly enhanced long-term sensitization. Taken together, the present results support a time-of-day influence on locomotor sensitization to cocaine.

Contribution of serotonin (5-HT) 5-HT2 receptor subtypes to the discriminative stimulus effects of cocaine in rats

The serotonin (5-hydroxytryptamine; 5-HT) 5-HT2 receptor (5-HT2R) family is an important regulator of the behavioral responsiveness to cocaine. The present study is an analysis of the role of the 5-HT2R subtypes (5-HT2AR, 5-HT2BR, and 5-HT2CR) in the discriminative stimulus effects of cocaine. Male Wistar rats were trained to discriminate cocaine (10 mg/kg) from saline in a two-lever, water-reinforced FR 20 task, and we investigated the ability of the 5-HT2AR antagonist 1(Z)-[2-(dimethylamino)ethoxyimino]-1(2-fluorophenyl)-3-(4-hydroxyphenyl)-2(E)-propene (SR 46349B), the 5-HT2BR antagonist N-(1-methyl-5-indolyl)-N'-(3-methyl-5-isothiazolyl) urea (SB 204741), and the 5-HT2CR antagonist [(+)-cis-4,5,7a,8,9,10,11,11a-octahydro-7H-10-methylindolo(1,7-bC)(2,6)naphthyridine (SDZ SER-082) to substitute for or to modulate the stimulus effects of cocaine. Pretreatment with SR 46349B (0.5-1 mg/kg) resulted in a rightward shift of the cocaine dose-response curve, while SDZ SER-082 (1 mg/kg) shifted the dose-response for cocaine to the left; SB 204741 (1-3 mg/kg) was inactive. Our pharmacological analyses of selective antagonists of 5-HT2AR, 5-HT2BR, and 5-HT2CR indicate oppositional influence of 5-HT2AR and 5-HT2CR on the stimulus effects of cocaine and exclude a role for the 5-HT2BR. These data suggest that 5-HT2AR and 5-HT2CR may be important in modulating the subjective effects of cocaine in humans.

Relationship of cocaine-induced c-Fos expression to behaviors and the role of serotonin 5-HT2A receptors in cocaine-induced c-Fos expression.

Serotonin 5-HT2A receptor antagonists have been shown to attenuate the locomotor stimulant effects of cocaine in rats. The present study used the expression of c-Fos protein as a marker to identify brain areas through which 5-HT2A receptors may modulate cocaine-induced behaviors. Significant correlations were observed between cocaine-induced hyperactivity and c-Fos expression in the nucleus accumbens core (NAcC), caudate-putamen (CPu), and subthalamic nucleus. In a separate experiment, a low, behaviorally relevant dose of cocaine was found to increase c-Fos immunoreactivity in the medial CPu, NAcC, and nucleus accumbens shell (NAcSh). The selective 5-HT2A receptor antagonist M100907 significantly attenuated cocaine-induced c-Fos expression in the medial CPu and in the NAcSh. These data suggest that 5-HT2A receptors in the NAcSh and CPu or in afferents to these regions may contribute to genomic responses to cocaine in the brain as well as to cocaine-induced locomotor activity.

Effect of GABA Agonists and GABA-A Receptor Modulators on Cocaine- and Food-Maintained Responding and Cocaine Discrimination in Rats

Recent studies indicate that GABAergic ligands modulate abuse-related effects of cocaine. The goal of this study was to evaluate the effects of a mechanistically diverse group of GABAergic ligands on the discriminative stimulus and reinforcing effects of cocaine in rats. One group of rats was trained to discriminate 5.6 mg/kg cocaine from saline in a two-lever, food-reinforced, drug discrimination procedure. In two other groups, responding was maintained by cocaine (0-3.2 mg/kg/injection) or liquid food (0-100%) under a fixed ratio 5 schedule. Six GABA agonists were tested: the GABA-A receptor agonist muscimol, the GABA-B receptor agonist baclofen, the GABA transaminase inhibitor gamma-vinyl-GABA (GVG), and three GABA-A receptor modulators (the barbiturate pentobarbital, the high-efficacy benzodiazepine midazolam, and the low-efficacy benzodiazepine enazenil). When tested alone, none of the compounds substituted fully for the discriminative stimulus effects of cocaine. As acute pretreatments, select doses of midazolam and pentobarbital produced 2.2- to 3.6-fold rightward shifts in the cocaine dose-effect function. In contrast, muscimol, baclofen, GVG, and enazenil failed to alter the discriminative stimulus effects of cocaine. In assays of cocaine- and food-maintained responding, midazolam and pentobarbital decreased cocaine self-administration at doses 9.6- and 3.3-fold lower, respectively, than those that decreased food-maintained responding. In contrast, muscimol, baclofen, and GVG decreased cocaine self-administration at doses that also decreased food-maintained responding. Enazenil failed to alter cocaine self-administration. Together with previous studies, these data suggest that among mechanistically diverse GABA agonists, high-efficacy GABA-A modulators may be the most effective for modifying the abuse-related effects of cocaine.

Binge self-administration and deprivation produces sensitization to the reinforcing effects of cocaine in rats.

Behavioral procedures that incorporate dynamic changes in drug-maintained behavior are needed to model the development of cocaine addiction in humans. Because sensitization may occur to some aspects of drug administration during the addiction process, the objective of the present study was to define the critical features of self-administration histories that result in subsequent increases in the reinforcing efficacy of cocaine (measured using the progressive ratio (PR) schedule). Animals were trained to self-administer cocaine on a fixed ratio (FR) schedule, baseline performance on a PR schedule was determined, and animals were given various histories of cocaine self-administration and drug deprivation. PR performance was reassessed following this experience. Cocaine self-administration under a discrete-trials procedure (24 h/day) for 10 days, followed by a 7-day deprivation period resulted in sensitization to the reinforcing effects of cocaine as assessed by the PR schedule (increases in maximal breakpoints maintained by cocaine with no change in sensitivity at lower doses). Similar levels of daily cocaine intake on a FR schedule (typically completed within 6 h) coupled with a deprivation period failed to produce changes in breakpoint. Providing access to cocaine during the "deprivation period" by repeated testing on a PR schedule prevented the sensitization. These data suggest that these self-administration-induced changes in breakpoint reflect sensitization, and show that a drug-free deprivation period is necessary, but not sufficient, to produce this increase.

Attenuation of d-amphetamine self-administration by baclofen in the rat: behavioral and neurochemical correlates

Recent reports have demonstrated that gamma-aminobutyric acid (GABA)-ergic compounds attenuate the reinforcing effects of cocaine in rats. Baclofen, a GABA(B) receptor agonist, appears to be particularly effective in this respect, suggesting that GABA(B) receptor activation is critically involved in mediating anti-cocaine effects. Amphetamine, like cocaine, is a psychomotor stimulant with high abuse potential in humans. The purpose of the present investigation was to determine whether baclofen may attenuate the reinforcing effects of d-amphetamine (dAMPH) in rats. Dose-response curves were generated to examine the effect of three doses of baclofen (1.8, 3.2 or 5.6 mg/kg, IP) on dAMPH intravenous self-administration (IVSA). Separate groups were trained to self-administer two doses of dAMPH (0.1 mg/kg or 0.2 mg/kg per injection) under either a fixed-ratio (FR) or progressive ratio (PR) schedule of reinforcement. Microdialysis was performed in an additional group of rats to examine the effect of baclofen on dAMPH-induced increases in dopamine (DA) efflux in the nucleus accumbens (NAc). Pretreatment with baclofen produced dose-dependent reductions in responding for dAMPH under both the FR and PR schedules, and attenuated dAMPH-induced increases in DA levels in the NAc. These results add to previous findings showing that baclofen attenuates the reinforcing effects of psychostimulant drugs, and suggest that further investigation into the effects of GABA(B) receptor agonists on drug self-administration is warranted.

Effect of thyrotropin-releasing hormone on the locomotor and sensitizing effects of cocaine in rats

The present study was designed to find out whether single and repeated treatment with thyrotropin-releasing hormone (TRH) changed the cocaine-evoked hyperactivation or sensitization, and whether cross-sensitization occurred between TRH and cocaine. Like cocaine (10 mg/kg), TRH (10 mg/kg) increased the basal activation of rats; however, when given in combination with cocaine (10 mg/kg), TRH (5–10 mg/kg) did not change the locomotor effect of cocaine. On day 10, cocaine challenge of rats treated repeatedly with the psychostimulant (days 1–5) significantly enhanced locomotor hyperactivity compared to the effect of acute cocaine injection in saline-treated (days 1–5) animals. When co-administered with cocaine for 5 days during the development of sensitization, TRH (10 mg/kg) enhanced the effect of the challenge dose of cocaine (10 mg/kg) following a 5-day withdrawal. Given acutely with cocaine on day 10 to cocaine-treated animals, TRH (5–10 mg/kg) did not change the expression of cocaine sensitization. Significant enhancement of the locomotor response to TRH (10 mg/kg) challenge was observed in animals treated repeatedly with TRH. The response to TRH (5–10 mg/kg) was stronger in repeated cocaine-treated rats than in saline-injected ones; similarly, the response to cocaine (10 mg/kg) was more potent in TRH-treated animals compared to saline-injected ones (cross-sensitization). In conclusion, our results indicate that exposure to TRH induces sensitization to its locomotor hyperactivity effect. They also show that TRH enhances the development of cocaine sensitization, but affects neither the expression phase of the phenomenon nor the locomotor hyperactivity induced by a single dose of cocaine. Moreover, cross-sensitization between cocaine and TRH has also been demonstrated. These findings also may provide an insight into the relationship between TRH and cocaine in humans exposed to the psychostimulant.

Effects of 5-HT 1B receptor ligands microinjected into the ventral tegmental area on the locomotor and sensitizating effects of cocaine in rats

The present study was aimed at finding out whether 5-HT 1B receptors located in the ventral tegmental area (VTA) played a role in the locomotor hyperactivity induced by a single dose of cocaine and in the sensitization evoked by repeated exposure to the psychostimulant in rats. Male Wistar rats, implanted bilaterally with cannulae in the VTA, were microinjected with GR 55562 (an antagonist of 5-HT 1B receptors) or CP 93129 (an agonist of 5-HT 1B receptors). GR 55562 (0.3–3 μg/side) did not affect locomotor hyperactivity response to a single dose of cocaine (10 mg/kg). CP 93129 in a dose of 1 μg/side (but not lower), which stimulated basal locomotor activity, enhanced the cocaine-induced locomotor hyperactivity. The rats that were treated repeatedly (for 5 days) with cocaine (10 mg/kg) and then challenged with cocaine (10 mg/kg) after 5-day withdrawal period (day 10 of the experiment) showed significantly higher locomotor hyperactivity compared to the effect observed in saline-pretreated and cocaine-challenged rats. GR 55562 (a dose of 3 μg/side, but not lower), administered for 5 days into the VTA just prior to daily cocaine, attenuated cocaine sensitization. When injected for 5 days into the VTA, CP 93129 (0.03–0.1 μg/side) enhanced the development of cocaine sensitization. The enhancing effect of CP 93129 (0.1 μg/side) was blocked by GR 55562 (1 μg/side). To examine the effects of GR 55562 and CP 93129 on the expression of cocaine sensitization, the 5-HT 1B receptor ligands were given acutely before the challenge dose of cocaine administered on day 10. No change in cocaine sensitization was observed after intra-VTA microinjections of GR 55562 (0.3–3 μg/side) or CP 93129 (0.1–1 μg/side). Our findings suggest that 5-HT 1B receptors located in the VTA play a permissive role in the development of cocaine sensitization, but are not involved in the locomotor hyperactivity induced by a single dose of cocaine or in the expression of the sensitization to the psychostimulant.

The GABA A receptor agonist muscimol modulates the locomotor, sensitizing and discriminative stimulus effects of cocaine in rats

The GABA A receptor agonist muscimol modulates the locomotor, sensitizing and discriminative stimulus effects of cocaine in rats

Mixed cocaine agonist/antagonist properties of (+)-methyl 4beta-(4-chlorophenyl)-1-methylpiperidine-3alpha-carboxylate, a piperidine-based analog of cocaine.

The present study investigated the pharmacological properties of a piperidine-based novel cocaine analog, namely, (+)-methyl 4beta-(4-chlorophenyl)-1-methylpiperidine-3alpha-carboxylic acid [(+)-CPCA]. Like cocaine, (+)-CPCA inhibited rat synaptosomal dopamine and norepinephrine uptake with high affinity, but was 33-fold less potent than cocaine in inhibiting serotonin uptake. Like cocaine, (+)-CPCA is a locomotor stimulant, although it was less potent and efficacious than cocaine. Importantly, pretreatment with (+)-CPCA dose dependently blocked the locomotor stimulant effects of cocaine in rats. (+)-CPCA completely substituted for cocaine in drug discrimination tests, although it was about 3 times less potent than cocaine. It was also self-administered by rats. Unexpectedly, (+)-CPCA did not enhance cocaine-induced convulsions in mice. As expected from rodent studies, rhesus monkeys readily self-administered (+)-CPCA. However, compared with cocaine, (+)-CPCA showed limited reinforcing properties in rats as assessed by both fixed and progressive ratio intravenous drug self-administration tests. These results collectively suggest that (+)-CPCA has an atypical pharmacological profile having both cocaine-like "agonist" and some cocaine "antagonist" properties. These properties of (+)-CPCA suggest that it may have utility in the treatment of cocaine craving and dependence.

Effects of 5-HT 1B receptor ligands microinjected into the ventral tegmental area on cocaine discrimination in rats

Some recent data indicate a significant interaction between serotonin (5-hydroxytryptamine; 5-HT) and dopamine in mesolimbic brain structures (e.g. the ventral tegmental area) which modulate the behavioral effects of cocaine in rats. The present study investigated the role of 5-HT 1B receptors in the ventral tegmental area in the discriminative stimulus effects of cocaine in rats. Male Wistar rats were trained to discriminate cocaine (10 mg/kg, intraperitoneally (i.p.)) from saline (i.p.) in a two-choice, water-reinforced fixed-ratio 20 procedure. After reaching the cocaine–saline discrimination criterion, the rats were stereotaxically implanted with bilateral cannulae in the ventral tegmental area and were then microinjected with selective 5-HT 1B receptor ligands. In substitution studies, microinjections of the 5-HT 1B receptor antagonist, 3-[3-(dimethylamino)propyl]-4-hydroxy- N-[4-(4-pyridinyl)phenyl]benzamide dihydrochloride (GR 55562; 0.1–1 μg/side), did not evoke cocaine-lever responding, whereas the 5-HT 1B receptor agonist, 1,4-dihydro-3-(1,2,3,6-tetrahydro-4-pyridinyl)-5 H-pyrrolo[3,2-b]pyridin-5-one (CP 93129; 0.3–1 μg/side), induced partial substitution for cocaine. Intra-tegmental microinjections with the 5-HT 1B receptor antagonist, GR 55562 (0.1–1 μg/side), before cocaine (5 mg/kg), which alone produced 98% cocaine-lever responses, decreased in a dose-dependent manner the discriminative stimulus effects of the psychostimulant. On the other hand, combination tests using a fixed dose of CP 93129 (0.3 or 1 μg/side), given into the ventral tegmental area prior to low systemic doses of cocaine (1.25–2.5 mg/kg), increased cocaine discrimination. These results seem to indicate that tegmental 5-HT 1B receptors are necessary to express the discriminative stimulus effects of cocaine.

Effects of serotonin (5-HT)(1B) receptor ligands, microinjected into accumbens subregions, on cocaine discrimination in rats.

Recent data indicate a significant input of serotonin (5-HT) on mesoaccumbens dopamine-dependent behavioral effects of cocaine in rats. The present study investigated the role of 5-HT(1B) receptors in nucleus accumbens subregions (the shell and the core) and the effect of stimulation of those receptors in the discriminative stimulus effects of cocaine in rats. Male Wistar rats were trained to discriminate cocaine (10 mg/kg, i.p.) from saline (i.p.) in a two-choice, water-reinforced fixed-ratio 20 procedure. After reaching the cocaine-saline discrimination criterion, rats were stereotaxically implanted with bilateral cannulae in the accumbens shell or core, and then were microinjected with selective 5-HT(1B) receptor ligands. In substitution studies, microinjections of the 5-HT(1B) receptor antagonist GR 55562 (0.1-10 microg/side) or the 5-HT(1B) receptor agonist CP 93129 (0.1-10 microg/side) into accumbens subregions did not evoke cocaine-lever responding. Pretreatment with the 5-HT(1B) receptor antagonist GR 55562 (0.1-10 microg/side) in the accumbens shell or core failed to modulate the discriminative stimulus effects of cocaine (5 mg/kg). Combination tests using a fixed dose of CP 93129 (1-10 microg/side) into the accumbens shell prior to cocaine administration (0.6-5.0 mg/kg) did not affect cocaine discrimination. CP 93129 (1 microg/side, but not 0.1 microg/side) microinjected in the accumbens core, and low doses of systemic cocaine (0.6-2.5 mg/kg) produced a leftward shift in the cocaine dose-response curve and a decrease in its ED(50) value. GR 55562 (1 microg/side) significantly attenuated the enhancement of cocaine discrimination evoked by a combination of CP 93129 (1 microg/side) and cocaine (1.25 mg/kg or 2.5 mg/kg). These results seem to exclude a major role for the accumbens shell and core 5-HT(1B) receptors in controlling the discriminative stimulus effects of cocaine. However, they do suggest that the stimulation of 5-HT(1B) receptors in the accumbens core, but not in the shell, enhances cocaine discrimination in rats.

Effects of a newly synthesized kappa-opioid receptor agonist, TRK-820, on the discriminative stimulus and rewarding effects of cocaine in rats.

We previously demonstrated that the prototypical kappa-opioid receptor agonist U-50,488H did not affect the discriminative stimulus effects of cocaine, and the dose of U-50,488H which significantly induced aversive effects attenuated the rewarding effects of cocaine. In the present study, the effects of a newly synthesized kappa-opioid receptor agonist, TRK-820, on the discriminative stimulus and rewarding effects of cocaine were examined in rats. In the drug discrimination procedure, the effects of TRK-820 on the discriminative stimulus effects of cocaine were examined in rats that had been trained to discriminate between 10 mg/kg cocaine and saline. TRK-820-induced place preference or place aversion and the effects of TRK-820 on the cocaine (4 mg/kg)-induced place preference were examined using a conditioned place preference procedure in rats. TRK-820 did not engender cocaine-like responding in rats trained to discriminate between 10 mg/kg cocaine and saline. In combination tests, low doses of TRK-820, which did not affect the response rate, significantly attenuated the discriminative stimulus effects of cocaine, and these effects of TRK-820 were reversed by a kappa-opioid receptor antagonist, nor-BNI. In the conditioned place preference procedure, low doses of TRK-820, which did not affect the response rate in the drug discrimination, did not produce either place preference or place aversion, whereas, higher dose (80 microg/kg) of TRK-820 slightly but significantly induced a place aversion. Under these conditions, the cocaine-induced place preference was completely attenuated by low doses of TRK-820. These results may prompt further investigation of the effectiveness of the new kappa-opioid receptor agonist TRK-820 as a novel pharmacotherapeutic compound for the treatment of cocaine addiction.